Compare OXSQ & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | ANTX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 129.8M |
| IPO Year | N/A | 2022 |
| Metric | OXSQ | ANTX |
|---|---|---|
| Price | $1.85 | $4.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 1.1M | 334.8K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 23.20% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.56 | $1.00 |
| 52 Week High | $2.56 | $6.91 |
| Indicator | OXSQ | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 70.62 |
| Support Level | $1.79 | $1.06 |
| Resistance Level | $1.95 | $6.91 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 52.50 | 81.23 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.